Navigation Links
Matinas BioPharma to Present at the NYC Medical Technology Forum on February 5, 2013
Date:2/4/2013

TEWKSBURY, N.J. and TARPON SPRINGS, Fla., Feb. 4, 2013 /PRNewswire/ -- Matinas BioPharma, Inc., a biopharmaceutical company focused on the commercialization and development of omega-3-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions, announced today that Roelof Rongen , Matinas BioPharma's Chief Executive Officer, is scheduled to present at the NYC Medical Technology Forum on Tuesday, February 5, 2013 at 6 PM EST.

Mr. Rongen's presentation will include the Company's business outlook for 2013, an overview of the development of its lead product candidate, MAT9001 and its key milestones expected over the next 12 months.  Matinas BioPharma is developing MAT9001 for therapeutic applications, with severe hypertriglyceridemia (TG>500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/dL) as the lead indications.  Based on promising early data, the Company is preparing to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and conduct a human study in 2013.  Following positive data from this study, Matinas expects to commence its Phase 3 registration program in the first half of 2014. 

About Matinas BioPharma

Matinas BioPharma Inc. is a privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions.  The Company is developing the investigational drug MAT9001 for therapeutic applications with severe hypertriglyceridemia (TG>500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/dL).  Matinas is building on its extensive, proprietary research and development capabilities of its founding management team.  The Matinas BioPharma team brings a cumulative multi-decade omega-3 pharmaceutical development experience to the Company with a proven track record, providing a unique perspective and capability for the development of the next generation of omega-3-fatty-acid-based pharmaceutical products. 

About The NYC Medical Technology Forum (NYC Medtech)

NYC Medtech is a professional platform that assists many different collaborators in the life science, biotech, device and pharma industries have successful outcomes.  This unique program not only brings together companies and investors but all people that are involved from reporters, scientists, academia, trade organizations, international partners et. al. The NYC Medtech program introduces its participants with relevant timely introductions whether through the website, email or the personal touch at the NYC Medtech Forum.  For more information about the NYC Medical Technology Forum visit www.nycmedtech.com.

CONTACT:   
Roelof Rongen
Matinas BioPharma, Inc.
+1-908-443-1870 
info@matinasbiopharma.com


'/>"/>
SOURCE Matinas BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
2. PDL BioPharma Announces Departure of Finance VP
3. PDL BioPharma Announces 2013 Regular Quarterly Dividends
4. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
5. FDAnews announces Biopharmaceutical Good Distribution Practices Summit
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. Robust Biopharmaceutical Pipeline Offers New Hope for Patients
8. Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
9. AAIPharma Appoints Senior Director of Biopharmaceutical Development
10. PDL BioPharma Announces Resignation of Chief Financial Officer
11. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016 Mylan N.V. (NASDAQ, TASE: MYL) today ... ended December 31, 2015. --> ... total revenues of $9.45 billion, up 28% on a ... revenues of $9.43 billion. Excluding the impact of the ... branded generics business (the "EPD Business"), full year adjusted ...
(Date:2/10/2016)... 10, 2016 CSI Specialty Group (CSI) expanded ... of the Specialty Pharmacy Podcast. A free, weekly show, ... providing real-world education, discussion and context amongst specialty pharmacy ... --> The Specialty Pharmacy Podcast, hosted ... Specialty Group Suzette DiMascio, CHE, CMCE, CPC, is available ...
(Date:2/10/2016)... , Feb. 10, 2016 Urologix, the ... the treatment of Benign Prostatic Hyperplasia (BPH), announces new ... Ash Keswani , a medical device industry veteran of ... the Limited Liability Company.  Plymouth, ... service lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, will ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... Glendale, CA (PRWEB) , ... February 10, 2016 , ... ... can be harder to find. Unfortunately, this can leave patients with dental emergencies at ... Glendale , is now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 ... more than 200 of the country’s top healthcare executives to share insights on ... benefit of the Forum is the provider-centric perspective, experience, expertise and strategy shared ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined ... readily available to physicians. The integration will enable Allscripts users to post open ... Everseat’s free mobile app. , The partnership gives Everseat substantial added power to ...
Breaking Medicine News(10 mins):